FDH (10-formyltetrahydrofolate dehydrogenase) is strongly downregulated in tumors while its elevation suppresses proliferation of cancer cells and induces p53-dependent apoptosis. We have previously shown that FDH induces phosphorylation of p53 at Ser6, which is a required step in the activation of apoptosis. In the present study, we report that FDH-induced p53 phosphorylation is carried out by JNK1 and JNK2 (c-Jun N-terminal kinases) working in concert. We have demonstrated that FDH induces phosphorylation of JNK1 and JNK2, while treatment of FDH-expressing cells with JNK inhibitor SP600125, as well as knockdown of JNK1 or JNK2 by siRNA, prevents phosphorylation of p53 at Ser6 and protects cells from apoptosis. Interestingly, the knockdown of JNK1 abolished phosphorylation of JNK2 in response to FDH, while knockdown of JNK2 did not prevent JNK1 phosphorylation. Pull-down assay with the p53-specific antibody has shown that JNK2, but not JNK1, is physically associated with p53. Our studies revealed a novel mechanism in which phosphorylation of JNK2 is mediated by JNK1 before phosphorylation of p53, and then p53 is directly phosphorylated by JNK2 at Ser6.
Introduction
The tumor suppressor protein p53, a short half-life transcription factor, is one of the major components in the apoptosis signaling (Vousden and Lu, 2002) . In response to different types of cellular stress, the p53 protein undergoes post-translational modifications that impair its degradation and result in accumulation of an active protein (Appella and Anderson, 2001; Oren, 2003) . Phosphorylation of p53, which occurs at multiple serine and threonine residues, is the most common p53 modification and is carried out by wide variety of protein kinases (Appella and Anderson, 2001) . Emerging evidence indicate that phosphorylation at a particular residue is specific in terms of both type of stress and a kinase performing the reaction, thus defining the selectivity of p53 action (Appella and Anderson, 2001; Vousden and Lu, 2002) .
Among other kinases regulating the p53 pathway are JNKs (c-Jun N-terminal kinases, also known as stressactivated protein kinases, SAPK), members of the MAPK (mitogen-activated protein kinase) family of proteins Kyriakis et al., 1994; Fuchs et al., 1998b) . JNKs are activated in response to cytokines or environmental stress and can induce both proapoptotic and pro-survival response (Weston and Davis, 2007) . In mammals, there are three JNK genes, Jnk1, Jnk2 and Jnk3; each JNK gene can produce multiple splice variants Kallunki et al., 1994; Gupta et al., 1996) . JNK1 and JNK2 are ubiquitously expressed in tissues, while expression of JNK3 is restricted to brain, heart and testis (Gupta et al., 1996) . Paradoxically, JNKs possess dual function toward p53. By direct binding, JNK targets p53 for ubiquitin-mediated degradation, which can be prevented by a peptide blocking the interaction of JNK with p53 (Fuchs et al., 1998a) . On the other hand, JNK participates in p53 phosphorylation resulting in p53 accumulation and activation as a transcriptional regulator (Milne et al., 1995; Hu et al., 1997; Fuchs et al., 1998b; Buschmann et al., 2001) . The opposite effects of JNK pathway on p53 could be associated with differential function of JNK genes/splice variants (Fogarty et al., 2003; Tafolla et al., 2005) .
One of the factors that activate p53 apoptotic pathways is FDH (10-formyltetrahydrofolate dehydrogenase) (Oleinik et al., 2005) . This folate enzyme is abundant in several tissues but is strongly downregulated in cancers (Krupenko and Oleinik, 2002) . Apparently, cancer cells decrease the expression of this enzyme to eliminate FDH activity, which is likely to interfere with cellular proliferation. Indeed, we have previously demonstrated that induction of FDH expression in FDH-deficient cancer cells induces apoptosis resulting in strong cytotoxicity (Oleinik and Krupenko, 2003) . However, it is not completely clear at present why FDH is detrimental to cancer cells. Although the enzymatic function of FDH, that is the conversion of 10-formyltetrahydrofolate to tetrahydrofolate, was known for decades, the main physiological role of the enzyme is still in question. Proposed FDH functions include regulation of reduced folate pools (Champion et al., 1994) , storage of the intracellular folate (Min et al., 1988) , regulation of de novo purine biosynthesis (Krupenko and Oleinik, 2002) and regulation of cellular methylation (Anguera et al., 2006) .
We have recently demonstrated that FDH-related apoptosis in A549 cells proceeds through the p53-dependent activation of PUMA (p53-upregulated modulator of apoptosis) that requires phosphorylation of p53 at Ser6 (Oleinik et al., 2005) . It has been reported that Ser6 of p53 can also be phosphorylated in response to ionizing radiation, UV light or etoposide treatment (Knippschild et al., 1997; Higashimoto et al., 2000) . While casein kinases, purified from murine cell lines, phosphorylate p53 at Ser6 (Knippschild et al., 1997) , kinases that could perform phosphorylation at this residue in human cells have not been identified so far. In the present study, we report that FDH-induced p53 phosphorylation is carried out by JNK2 working in concert with JNK1. This occurs through a mechanism in which phosphorylation of JNK2 is mediated by JNK1 before phosphorylation of p53, and then p53 is phosphorylated by JNK2 at the specific residue, Ser6.
Results

FDH activates JNK pathway
We have studied whether accumulation of p53 in FDHinduced cells is associated with activation of MAP kinases. In vitro kinase activity assays of p38, ERK1/2 and JNK1/2 in lysates of A549 cells revealed only the activation of JNK1/2 after FDH expression ( Figure 1a , strong increase of phosphorylated c-Jun is seen). This activation coincides with the sharp increase of phosphorylated JNKs occurring by 24 h FDH post-induction and accumulation of p53 while the overall levels of JNKs were not changed (Figure 1b) . In contrast, levels of phosphorylated p38 and ERK1/2 were essentially unaffected ( Figure 1b) . Of note, endogenous levels of c-Jun, the JNK substrate and its phosphorylated form were not changed upon FDH expression (Figure 1b) . Phosphorylation of JNKs after FDH expression was confirmed by staining cells with specific antibody against phosphorylated JNK1/2 (Figure 1c) . The phosphorylated JNKs in our experiments were localized to the nuclei (Figure 1c ).
The JNK inhibitor blocks FDH-induced p53 accumulation and protects cells against FDH-induced antiproliferative effects To explore further the role of JNK1/2 in cellular response to FDH, we have studied whether the inhibitors of JNK1/2 could prevent p53 accumulation, and associated cytotoxicity, in FDH-induced cells. To ensure that targeting of JNK is specifically relevant to FDH effects, inhibitors of two other commonly activated MAP kinases, p38 and ERK1/2, were also tested in these experiments. The following inhibitors were used: SP600125 (JNK) (Bennett et al., 2001) , SB203580 (p38) (Davies et al., 2000) and ERK activation inhibitor peptide II (ERK1/2) (Kelemen et al., 2002) . At concentration of 10 mM, the JNK inhibitor almost completely blocked p53 accumulation 48 h FDH post-induction while inhibitors of p38 or ERK1/2 did not reveal notable effects (Figure 2a JNK is a mediator of FDH-induced apoptosis JNK inhibitor SP600125 in our experiments suppressed FDH-induced apoptosis (Figure 3a) , and prevented both accumulation of PUMA (the p53 downstream target in FDH-induced apoptosis) and release of cytochrome c to cytosol (Figure 3b ). FDH-induced apoptosis proceeds through the activation of caspase-9 and caspase-3 (Oleinik and Krupenko, 2003; Oleinik et al., 2005) . Treatment of FDH-expressing cells with the pan-caspase inhibitor z-VAD rescued the cells from apoptotic death (Figure 3c ), but did not prevent JNK1/2 phosphorylation ( Figure 3d ) indicating that JNK activation is an early step in the FDH-signaling pathway, upstream of caspases. Accordingly, treatment with SP600125 inhibitor significantly decreased caspase-9/6 activation in response to FDH induction ( Figure 3e ). More profound effect is seen at day 4 (although it is also noticeable at earlier time points) indicating that activation of caspases in FDH-induced apoptosis is a late event. These experiments as well as our previous studies (Oleinik et al., 2005) indicate that FDH induces intrinsic apoptotic pathways in A549 cells. Absence of Bid cleavage, a common indication of extrinsic apoptotic pathway, supports this conclusion ( Figure 3b ).
JNK specifically phosphorylates p53 at Ser6
Phosphorylation of p53 at Ser6 is crucial for mediation of FDH suppressor effects (Oleinik et al., 2005) . We have observed concentration-dependent decrease in accumulation of p53 and its phosphorylation at Ser6 in the presence of SP600125 inhibitor in A549 cells ( Figure 4a ). Similar results were obtained in experiments with another cell line, H1299 (non-small cell lung carcinoma). H1299 cells are both FDH and p53 deficient. We have previously shown that expression of p53 and FDH (by simultaneous transfection) in these cells resulted in phosphorylation of p53 at Ser6 (Oleinik et al., 2005) . Treatment of these cells with SP600125 inhibitor decreased FDH-dependent phosphorylation of p53 at Ser6 (Figure 4b ). In these experiments mutant p53, in which two serine residues (Ser20 and Ser392) were replaced with alanine, was expressed in H1299 cells. Elimination of these two residues, which can be also phosphorylated in response to FDH expression (Oleinik et al., 2005) , allowed specific evaluation of the events associated with Ser6 phosphorylation. We observed that cells with simultaneous knockdown of JNK1 and JNK2 were not sensitive to FDH expression compared with the original cells possessing both JNKs, in which strong inhibition of proliferation has been seen after FDH induction (Figure 5b , inset shows that the corresponding JNK is silenced). Interestingly, it appears that both JNK1 and JNK2 are required to mediate FDH suppressor effects: knockdown of either kinase protected cells against FDH-induced cytotoxicity with essentially no additive effects of their combined silencing ( Figure 5b) . Likewise, accumulation of p53 and phosphorylation at Ser6 were seen only in the cells that possess both JNK1 and JNK2 (Figure 5a ). Significant decrease in the levels of phosphorylated JNKs and p53 after FDH induction was seen in JNK1/2 knocked down cells (Figure 5c ). Overall, these results demonstrated that the JNK-deficient cells were not sensitive to FDH suppressor effects. 
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Both, JNK1 and JNK2, are required to mediate FDH suppressor effects Our experiments suggest that both JNK1 and JNK2 are required to induce p53 pathway in A549 cells. We have hypothesized that, in response to FDH induction, one of the JNKs mediates the phosphorylation of the other, which in turn, phosphorylates p53. In support of this hypothesis, the knockdown of JNK2 did not affect the levels of phosphorylated JNK1 (Figure 6a and b) . In contrast, when JNK1 was knocked down, significant decrease of phosphorylated JNK2 was observed without the decrease in its total protein levels (Figure 6a and b) . These results demonstrated that in the FDH-induced apoptotic cascade JNK1 is phosphorylated independently of JNK2, while phosphorylation of JNK2 requires the prior phosphorylation of JNK1. Requirement for both kinases in p53 phosphorylation was further confirmed by in vitro kinase assays. In these experiments, we used A549 cells with stable p53 siRNA knockdown (Oleinik et al., 2005) ; they do not express detectable levels of endogenous p53 (Figure 6c ). The lysates from FDH-induced cells were incubated with the purified recombinant p53, which was then pulled down by the p53-specific antibody and bead-immobilized protein G with the expectation that the last kinase in the pathway will be co-precipitated enabling phosphorylation of p53 in vitro. Indeed, addition of ATP to the immunoprecipitated p53 resulted in phosphorylation at Ser6 (Figure 6c, lane 2) . In agreement with the concerted action of both kinases, the in vitro p53 phosphorylation was lost in the experiments with either lysate from JNK1 or JNK2-knocked down cells (Figure 6c , lanes 3 and 4, correspondingly), but was restored by mixing the two lysates (Figure 6c, lane 6) . We have further identified JNK2 as the pulled down product (Figure 6c ), thus demonstrating that it is the end-pathway kinase responsible for direct phosphorylation of p53 at Ser6 in this system (Figure 6c , no traces of JNK1 were present after pull-down experiments). Similar results were obtained in experiments with another cell line, 
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NV Oleinik et al p53-deficient H1299, further proving direct phosphorylation of p53 by JNK2 in response to FDH (data not shown).
Discussion
Previously, we have reported that expression of FDH in p53-proficient cancer cells caused p53-dependent apoptosis, while the knockdown of p53 protected cells from FDH suppressor effects (Oleinik et al., 2005) . It has been further found that phosphorylation of p53 at Ser6 is a crucial event in triggering FDH-dependent apoptosis. Among other p53 modifications phosphorylation at Ser6 is not the most common, and it is not clear what kinases can preferentially act on this site. Here, we present the evidence that (1) FDH-dependent activation of p53, as well as Ser6 phosphorylation, requires two kinases, JNK1 and JNK2 and (2) there is a signaling cascade in which FDH induces phosphorylation of JNK1 that subsequently mediates phosphorylation of JNK2, and thus activated JNK2 directly phosphorylates Ser6 of p53. Our study has demonstrated that expression of FDH in A549 cells induces phosphorylation of JNK1 and JNK2. We have also observed that treatment of FDH-expressing cells with an ATP-competitive JNKspecific inhibitor, SP600125 (Bennett et al., 2001) , prevented FDH-induced apoptosis and promoted cell survival. Although selectivity of this inhibitor was in question after a recent study demonstrating that it inhibits other kinases (Bain et al., 2003) , at lower concentrations used in our experiments, it preferentially targets JNKs (Du et al., 2004) . Similar protective effects against FDH toxicity were observed after siRNA silencing either JNK1 or JNK2. We have further demonstrated that treatment with both the inhibitor and synthetic siRNAs prevented phosphorylation of p53 at Ser6, a required event in FDH-induced apoptosis (Oleinik et al., 2005) . Since knockdown of either of the kinases protected cells against FDH-related stress, we concluded that both JNK1 and JNK2 are positive modulators of p53Ser6 phosphorylation and are essential to activate the p53 pathway in this system. The pull-down experiments followed by the in vitro kinase assay further revealed that JNK2 is the kinase directly phosphorylating p53 at Ser6, while JNK1 is a required positive upstream mediator of JNK2 phosphorylation.
The early finding that combined JNK1 and JNK2 knockout is embryonic lethal, while mice deficient in JNK1-and JNK2-dependent p53 phosphorylation NV Oleinik et al either of the genes are morphologically normal (Kuan et al., 1999; Sabapathy et al., 1999) suggested redundant functions of the two genes. Indeed, both JNK1 and JNK2 function similarly in regulating apoptosis and proliferation of T cells (Sabapathy et al., 1999) . At the same time, antagonistic functions of JNK1 and JNK2 in regulating of c-Jun have been demonstrated (Sabapathy et al., 2004) . It has also been reported that JNK1 and JNK2 oppositely regulate p53 (Fogarty et al., 2003; Tafolla et al., 2005) : downregulation of JNK2 by antisense oligonucleotides suppressed p53 levels in primary human fibroblasts, while knockdown of JNK1 resulted in increased levels of p53. Of note, JNK1 and JNK2 can inhibit phosphorylation of each other, apparently by competing for the same upstream kinases (Liu et al., 2004) . Strikingly, our studies have demonstrated a distinct mode of interplay between JNK1 and JNK2: the two kinases cooperate with each other, in nonredundant manner, representing a single signaling cascade. An interesting feature of FDH-related JNK activation is that c-Jun, a canonical downstream target of JNKs (Kyriakis et al., 1994) , was not phosphorylated in response to FDH expression suggesting that the FDHactivated JNK pathway proceeds in bypass of the c-Jun signaling. This conclusion received additional support from our experiments with a peptide analog of the kinase interactive motif of the scaffold protein, which inhibits JNK activity toward c-Jun (Barr et al., 2002) . Treatment with this inhibitor did not protect cells from FDH cytotoxic effects (data not shown). Inactive c-Jun pathway is in agreement with its function in cell survival and differentiation observed in various models (Bost et al., 1999; Smith et al., 1999; Wisdom et al., 1999) . Negative regulation of p53 transcription by c-Jun could take a part in survival mechanism . Interestingly, this pathway, which would interfere with FDH suppressor effects, was not operative in our system. It has been proposed that distinction between survival and apoptotic JNK pathways depends on the duration of the stress signal: activation of JNK by a short exposure to stress leads to cell survival while prolonged stimulation causes apoptosis (Xia et al., 1995; Ventura et al., 2006) . Since after induction, FDH is present in the cell for a long period of time, due to a long half-life, perhaps this lengthy exposure to FDH-induced stress diverts JNK-related signals toward apoptosis. Of note, modulation of FDH effects by JNK is distinct from JNK function in integration of intrinsic and extrinsic pathways where cleavage of Bid, a BH3-domain only member of Bcl-2 family, is a required step (Tournier et al., 2000) .
In summary, a novel mechanism of activation of p53-dependent apoptosis, revealed in these studies, requires participation of two JNKs, JNK1 and JNK2. However, only JNK2 is found to be physically associated with p53, implicating this kinase in phosphorylation of p53 at Ser6. It has been previously demonstrated that JNK1 can phosphorylate Ser34 of p53 in response to UV irradiationinduced stress in a derivative of NIH3T3 cell line (Milne et al., 1995; Hu et al., 1997) . It has been also shown that JNK2 phosphorylates p53 at Thr81 in response to UV light (Buschmann et al., 2001) . In addition, activation of JNK1, but not JNK2, is related to phosphorylation of p53 at Ser 15 in b-amyloid peptide-induced apoptosis in cultured neurons (Fogarty et al., 2003) . Our studies indicate that FDH activates a distinct JNK-related signaling cascade that recruits both JNK1 and JNK2.
Materials and methods
Reagents MAP kinase inhibitors were obtained from Calbiochem (San Diego, CA, USA) (ERK1/2 Activation Inhibitor peptide II, SB203580 and JNK Inhibitor I, (L)-form) and Sigma (St Louis, MO, USA) (SP600125). Stock solutions of the inhibitors were prepared in dimethyl sulfoxide (DMSO) or water. Inhibitors were added to the cell culture 24 h FDH postinduction; after that media containing inhibitor were replaced every 48 h.
Cell culture
Cell media and reagents were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise indicated. Antibiotics and Tet-certified serum were purchased from Clontech (Mountain View, CA, USA). Tet-On A549/FDH stable cell line for inducible FDH expression and p53-deficient A549 cell line were generated in our previous studies (Oleinik and Krupenko, 2003; Oleinik et al., 2005) . H1299 cells (non-small cell lung carcinoma) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay using a CellTiter 96 kit (Promega, Madison, WI, USA).
Transient transfection
Expression of FDH in p53-deficient A549 cells (a stable clone of A549 cell line expressing p53-targeting siRNA) (Oleinik et al., 2005) and simultaneous expression of FDH and p53 in H1299 cells were achieved by transient transfection using Lipofectamine 2000 (Invitrogen). Transfecting vectors were pcDNA3.1/FDH and pCEP/p53 (Oleinik et al., 2005) . In control experiments, 'empty' vectors pcDNA3.1 and pCEP were used. Experiments were performed in six-well plates with approximately 2.5 Â 10 5 cells seeded per well 24 h before transfection. In a parallel set of experiments, co-transfection with pEGFP-N3 plasmid was carried out to ensure similar transfection efficiency between experiments. Transfection efficiency achieved in these experiments was between 40 and 50%. Experiments were repeated at least three times, showing less than 30% variability.
In vitro kinase activity assays In vitro assays of p38, JNK and ERK1/2 activities were performed using MAP Kinase Assay Kits (Cell Signaling Technology, Danvers, MA, USA) according to manufacturer's manual. Kinase activities were evaluated based on the phosphorylation of, ATF-2 (Livingstone et al., 1995) , c-Jun (Leppa and Bohmann, 1999) and Elk-1 (Gille et al., 1995) . Levels of phosphorylated substrates were assessed by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrolysis) followed by immunoblot assays with specific antibodies.
In the in vitro kinase assay with p53 as a kinase substrate, the p53 knockdown A549 cells or H1299 cells were simultaneously transfected with siRNA (targeting JNK1, JNK2 or both) and with the FDH expression vector. Cells transfected with the FDH expression vector and scrambled siRNA served as a positive control. Forty-eight hours posttransfection, cell lysates from 2.5-5 Â 10 6 cells were incubated with 5 mg of purified recombinant p53 for 4 h at 41C followed by 2 h incubation with 2.5 mg of p53-specific antibody (OP-6, Oncogene, San Diego, CA, USA). Protein A Sepharose 4 Fast Flow (50 ml of 50% slurry) has been added to the preparation and incubated overnight with constant agitation. Sepharose beads were washed three times with 25 mM Tris-HCl buffer, pH 7.5 containing 5 mM b-glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na 3 VO 4 and 10 mM MgCl 2 , and incubated in 50 ml of the same buffer containing 200 mM ATP, for 30 min at 301C. Phosphorylation of p53 at Ser6 was evaluated by SDS-PAGE followed by immunoblotting assays with phospho-Ser-6-p53 specific polyclonal antibodies (Cell Signaling Technology).
Assay of apoptosis
Apoptosis was detected by Annexin-V labeling using an Annexin-V-FLUOS Staining Kit (Roche Molecular Biochemicals, Indianapolis, IN, USA) or by assaying caspase-9/6 using ApoAlert Caspase Assay Kit (Becton-Dickinson, Franklin Lakes, NJ, USA).
Antibodies FDH was detected using FDH-specific polyclonal antiserum (1:10 000); p53 and actin were detected using monoclonal antibodies (Calbiochem) (0.1 mg/ml and 1:5000, respectively). Polyclonal antibodies against phosphorylated p53 were from AnaSpec (San Jose, CA, USA) (Ser-6, 1.5 mg/ml), Cell Signaling Technology (Ser-392, 1:500) and Santa Cruz Biotechnology (Santa Cruz, CA, USA) 1:200) . SAPK/JNK and Phospho-SAPK/JNK (Thr183/Tyr185) were detected using polyclonal antibodies from Cell Signaling Technology (1:500 in both cases) or C17 and N18 polyclonal antibodies against JNK1 and JNK2, correspondingly (Santa Cruz Biotechnology). Bid and phosphorylated c-Jun (Ser63) and ATF-2 (Thr 71) were detected using Cell Signaling Technology polyclonal antibodies (1:500). Polyclonal antibody against PUMA was from ProSci Inc. (Poway, CA, USA) (used at 2 mg/ml concentration). Anti-cytochrome C monoclonal antibody (clone 7H8.2C12) was from BD PharMingen (Franklin Lakes, NJ, USA) (used at 0.5 mg/ml concentration). In all experiments, a Hybond TM-ECL nitrocellulose membrane and an ECL detection kit (both from GE Amersham Pharmacia Biotech, Piscataway, NJ, USA) were used. In each case, membranes were stripped and re-probed for the levels of actin.
Immunofluorescence ATG10.26 cells were seeded in Lab-Tek II Chamber (Nulg Nunc International, Rochester, NY, USA) and induced with Dox for FDH expression for the indicated periods of time. Slides were fixed for 5 min with absolute methanol at À101C, air-dried and incubated for 30 min in phosphate-buffered saline (PBS) containing 10% (v/v) goat serum. Incubation with primary JNK1/2 and phospho-JNK1/2 antibody (Cell Signaling Technology, 1:25 dilution) was performed for 1 h followed by incubation with secondary goat anti-mouse antibodies labeled with Alexa Fluor 488 (Molecular Probes, Carlsbad, CA, USA, 5 mg/ml) in a dark chamber for 45 min and counterstaining with TO-PRO-3 iodide (Molecular Probes). After each step, slides were washed with the PBS. Slides were mounted with VECTASHIELD HardSetTM Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Fluorescent images were captured and processed using a Leica TCS SP2 AOBS scanning Confocal microscope.
Colony formation assay
Colony formation by Tet-On/FDH A549 cells after treatment with JNK inhibitor SP600125, or transfection with siRNA was assessed 2-3 weeks after induction of FDH expression by Dox. Colonies were visualized by staining with 0.2% crystal violet. The number of colonies was analysed using Quantity One software (BioRad, Hercules, CA, USA).
